Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (NCT04150068)

🧪 Interventions in This Study

• Oral Lenacapavir (DRUG)
• Oral Lenacapavir Placebo (DRUG)
• Subcutaneous Lenacapavir (DRUG)
• Failing ARV Regimen (DRUG)
• Optimized Background Regimen (OBR) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (75 Sites)

Showing the first 25 of 75 sites.

• Ruane Clinical Research Group Inc — Los Angeles, California
• Mills Clinical Research — Los Angeles, California
• Eisenhower Health Center at Rimrock — Palm Springs, California
• One Community Health — Sacramento, California
• Yale University; School of Medicine — New Haven, Connecticut
• Washington Health Institute — Washington D.C., District of Columbia
• Midland Florida Clinical Research Center, LLC — DeLand, Florida
• Gary J. Richmond, M.D., P.A. — Fort Lauderdale, Florida
• Midway Immunology and Research Center — Ft. Pierce, Florida
• Floridian Clinical Research — Hialeah, Florida
• AIDS Healthcare Foundation - South Beach — Miami Beach, Florida
• Orlando Immunology Center — Orlando, Florida
• St. Joseph's Hospital Comprehensive Research Institute — Tampa, Florida
• Triple O Research Institute, P.A. — West Palm Beach, Florida
• Emory Hospital Midtown Infectious Disease Clinic — Atlanta, Georgia
• Atlanta ID Group, PC — Atlanta, Georgia
• Chatham County Health Department — Savannah, Georgia
• Howard Brown Health Center — Chicago, Illinois
• Northstar Healthcare — Chicago, Illinois
• Be Well Medical Center — Berkley, Michigan
• Southampton Healthcare, Inc. — St Louis, Missouri
• New York-Presbyterian/Queens — Flushing, New York
• North Shore University Hospital/Division of Infectious Diseases — Manhasset, New York
• Jacobi Medical Center — The Bronx, New York
• Atrium Health- Infectious Disease Consultants — Charlotte, North Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HIV-1-infection

• Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 — Washington D.C., District of Columbia
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen — Berkeley, California
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1 — Birmingham, Alabama
• Impact of HIV-1 and Aging on Mucosal Vaccine Responses — Aurora, Colorado
• Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed — Birmingham, Alabama
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy — Phoenix, Arizona

Explore by condition: All HIV-1-infection clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.